GUARD THERAPEUTICS INTERNATIONAL AB

Insiders Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 11/09/2024 BST			5-day change	1st Jan Change
29.00 ^SEK	0.00%		+4.32%	-18.99%

08-29	First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER	CI
08-27	Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study	MT

Insiders

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Guard Therapeutics International AB Appoints Nomination Committee for 2024	12-07	CI
Guard Therapeutics International AB Announces Nomination Committee Appointments	20/12/22	CI
Guard Therapeutics International AB Appoints Torbjörn Larsson as Head of CMC (Chemistry, Manufacturing and Controls), Effective 1 May 2022	26/04/22	CI
Guard Therapeutics Appoints Michael Reusch as Chief Medical Officer, Effective January 1, 2022	15/12/21	CI
Guard Therapeutics appoints Sara Thuresson as Head of Clinical Operations	15/02/21	CI
Guard Therapeutics Appoints Ann-Kristin Myde as Head of Global Project Management, Effective 1 April 2021	28/12/20	CI
Guard Therapeutics Appoints Peter Gilmour as Head of Preclinical Science, Effective 1 August 2020	06/07/20	CI
A1M Pharma Appoints Tobias Larsson Agervald as Chief Medical Officer	14/08/18	CI
A1M Pharma Appoints Martin Austin as Business Development Director	25/09/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW